Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Stacchiotti, Silvia [VerfasserIn]   i
 Van der Graaf, Winette T. A. [VerfasserIn]   i
 Sanfilippo, Roberta G. [VerfasserIn]   i
 Marreaud, Sandrine I. [VerfasserIn]   i
 Van Houdt, Winan J. [VerfasserIn]   i
 Judson, Ian R. [VerfasserIn]   i
 Gronchi, Alessandro [VerfasserIn]   i
 Gelderblom, Hans [VerfasserIn]   i
 Litiere, Saskia [VerfasserIn]   i
 Kasper, Bernd [VerfasserIn]   i
Titel:First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma
Titelzusatz:an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis
Verf.angabe:Silvia Stacchiotti, Winette T.A. Van der Graaf, Roberta G. Sanfilippo, Sandrine I. Marreaud, Winan J. Van Houdt, Ian R. Judson, Alessandro Gronchi, Hans Gelderblom, Saskia Litiere, and Bernd Kasper
E-Jahr:2022
Jahr:13 May 2022
Umfang:7 S.
Fussnoten:Gesehen am 06.11.2023
Titel Quelle:Enthalten in: Cancer
Ort Quelle:New York, NY : Wiley-Liss, 1948
Jahr Quelle:2022
Band/Heft Quelle:128(2022), 15 vom: Aug., Seite 2932-2938
ISSN Quelle:1097-0142
Abstract:BACKGROUND No prospective trial with anthracycline-based chemotherapy has individually assessed response in a well-differentiated (WD)/dedifferentiated (DD) liposarcoma patient cohort. We conducted a retrospective analysis of first-line chemotherapy in liposarcoma of intra-abdominal origin (IA-LPS) in patients who had entered the European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) trials. METHODS We searched for all adult patients treated with first-line chemotherapy for advanced IA-LPS in the EORTC STBSG phase 2 and 3 trials from 1978. Treatment was aggregated into 5 groups: anthracycline alone, ifosfamide alone, doxorubicin plus ifosfamide (D+IFO), doxorubicin/cyclophosphamide/vincristine/dacarbazine, and “other” (brostallicin, trabectedin). Response was assessed prospectively by Response Evaluation Criteria in Solid Tumors or World Health Organization criteria. Progression-free survival (PFS) and overall survival (OS) were computed by Kaplan-Meier method. RESULTS A total of 109 patients with IA-LPS from 13 trials were identified (104 evaluable for response). Overall, there were 10/109 (9.2%) responders: 3/48 (6.3%) in the anthracycline alone group, 2/15 (13%) in the ifosfamide alone group, and 4/18 (22%) in the D+IFO group. At the 10-month median follow-up (interquartile range, 6-24), the median OS was 19 months (95% CI, 15-21) and median PFS 4 months (95% CI, 3-6). D+IFO achieved a not statistically significant longer median PFS (12 months) and median OS (31 months) than observed with other regimens. Univariate/multivariate analysis did not identify prognostic factors. CONCLUSIONS Cytotoxic chemotherapy, in particular anthracycline alone, had marginal activity in advanced IA-LPS. Ifosfamide-containing regimens showed higher activity, although it was not statistically significant and in a small number of cases, with the combination of doxorubicin and ifosfamide appearing to be the more active regimen available in fit patients. This series provides a benchmark for future trials on new drugs in WD/DD liposarcoma.;
DOI:doi:10.1002/cncr.34264
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1002/cncr.34264
 kostenfrei: Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34264
 DOI: https://doi.org/10.1002/cncr.34264
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:anthracycline
 chemotherapy
 doxorubicin
 epirubicin
 ifosfamide
 liposarcoma
 sarcoma
K10plus-PPN:1869367596
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69139769   QR-Code
zum Seitenanfang